This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
Sponsor: University of Virginia
Merck Sharp & Dohme LLC
Otsuka Pharmaceutical Development & Commercialization, Inc.
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03240211
Contact: Marian Abdelmalek, MS 434-924-8827 email@example.com
Contact: Justin Alicea 434-243-5350 firstname.lastname@example.org